Alexandrov, A. V. et al. (2019) Endovascular equipoise shift in a phase III randomized clinical trial of sonothrombolysis for acute ischemic stroke. Therapeutic Advances in Neurological Disorders, 12, (doi: 10.1177/1756286419860652) (PMID:31320933) (PMCID:PMC6628520)
|
Text
190685.pdf - Published Version Available under License Creative Commons Attribution Non-commercial. 558kB |
Abstract
Background: Results of our recently published phase III randomized clinical trial of ultrasound-enhanced thrombolysis (sonothrombolysis) using an operator-independent, high frequency ultrasound device revealed heterogeneity of patient recruitment among centers. Methods: We performed a post hoc analysis after excluding subjects that were recruited at centers reporting a decline in the balance of randomization between sonothrombolysis and concurrent endovascular trials. Results: From a total of 676 participants randomized in the CLOTBUST-ER trial we identified 52 patients from 7 centers with perceived equipoise shift in favor of endovascular treatment. Post hoc sensitivity analysis in the intention-to-treat population adjusted for age, National Institutes of Health Scale score at baseline, time from stroke onset to tPA bolus and baseline serum glucose showed a significant (p < 0.01) interaction of perceived endovascular equipoise shift on the association between sonothrombolysis and 3 month functional outcome [adjusted common odds ratio (cOR) in centers with perceived endovascular equipoise shift: 0.22, 95% CI 0.06–0.75; p = 0.02; adjusted cOR for centers without endovascular equipoise shift: 1.20, 95% CI 0.89–1.62; p = 0.24)]. After excluding centers with perceived endovascular equipoise shift, patients randomized to sonothrombolysis had higher odds of 3 month functional independence (mRS scores 0–2) compared with patients treated with tPA only (adjusted OR: 1.53; 95% CI 1.01–2.31; p = 0.04). Conclusion: Our experience in CLOTBUST-ER indicates that increasing implementation of endovascular therapies across major academic stroke centers raises significant challenges for clinical trials aiming to test noninterventional or adjuvant reperfusion strategies.
Item Type: | Articles |
---|---|
Additional Information: | The authors disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: RM has been supported by the National Program of Sustainability II (MEYS CR; project number LQ1605) and by FNUSAICRC (project number CZ.1.05/1.1.00/02.0123; OP VaVpI); AHK has been supported by a Research Experience Fellowship from the European Academy of Neurology. |
Status: | Published |
Refereed: | Yes |
Glasgow Author(s) Enlighten ID: | Muir, Professor Keith |
Authors: | Alexandrov, A. V., Tsivgoulis, G., Köhrmann, M., Katsanos, A. H., Soinne, L., Barreto, A. D., Rothlisberger, T., Sharma, V. K., Mikulik, R., Muir, K. W., Levi, C. R., Molina, C. A., Saqqur, M., Mavridis, D., Psaltopoulou, T., Vosko, M. R., Fiebach, J. B., Mandava, P., Kent, T. A., Alexandrov, A. W., and Schellinger, P. D. |
College/School: | College of Medical Veterinary and Life Sciences > School of Psychology & Neuroscience |
Journal Name: | Therapeutic Advances in Neurological Disorders |
Publisher: | SAGE Publications |
ISSN: | 1756-2856 |
ISSN (Online): | 1756-2864 |
Copyright Holders: | Copyright © 2019 The Authors |
First Published: | First published in Therapeutic Advances in Neurological Disorders 12 |
Publisher Policy: | Reproduced under a Creative Commons license |
University Staff: Request a correction | Enlighten Editors: Update this record